Brief: ESSA Pharma Says Clinical Study Is Expected To Start In 2021 For Combination Of EPI-7386 And Darolutamide

ESSA Pharma

28/04/2021 12:44

April 28 (Reuters) - ESSA Pharma Inc  EPIX.O :
    * ESSA PHARMA ANNOUNCES CLINICAL COLLABORATION AGREEMENT
WITH
BAYER TO EVALUATE THE COMBINATION OF EPI-7386 AND DAROLUTAMIDE
IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    * ESSA PHARMA - UNDER TERMS OF AGREEMENT, BAYER MAY SPONSOR
&
CONDUCT A PHASE 1/2 STUDY FOR COMBINATION OF EPI-7386 &
DAROLUTAMIDE IN MCRPC PATIENTS
    * ESSA PHARMA INC - ESSA WILL SUPPLY EPI-7386 FOR TRIAL AND
WILL
RETAIN ALL RIGHTS TO EPI-7386
    * ESSA PHARMA INC - CLINICAL STUDY IS EXPECTED TO START IN
2021
FOR  COMBINATION OF EPI-7386 AND DAROLUTAMIDE

Source text for Eikon:  ID:nPn75wztRa 
Further company coverage:  EPIX.O 

 ((Reuters.Briefs@thomsonreuters.com;))